4C Medical Secures $175M Series D Financing to Advance TMVR Technology

Minnesota-based 4C Medical Technologies has closed a Series D financing round of up to $175 million, led by Boston Scientific Corporation, to advance the clinical development and commercialization of its AltaValve™ System. The AltaValve™ System is a next-generation transcatheter mitral valve replacement (TMVR) technology designed to treat patients with moderate-to-severe or severe mitral regurgitation (MR) who are unsuitable for surgery or transcatheter edge-to-edge repair.

The funding will primarily support the ongoing global pivotal trial ATLAS (A Transseptal Left Atrial System for Treatment of Mitral Regurgitation) in the U.S. and Europe. Enrollment for the ATLAS trial began in the U.S. in October 2024. The trial aims to evaluate the safety and effectiveness of the AltaValve™ System in addressing MR, a progressive valvular heart disease affecting nearly 10% of Americans aged 75 and older. MR occurs when the mitral valve leaflets fail to close properly, causing blood to leak backward into the left atrium. If untreated, it can lead to atrial fibrillation, pulmonary hypertension, heart failure, and death.

“This financing and the participation of Boston Scientific are timely as we continue enrollment in our global ATLAS pivotal trial,” said Jeff Chambers, M.D., Chairman of the Board at 4C Medical. “With a strong management team and trial leadership, this funding strategically positions us to accelerate progress toward device commercialization.”